Study analysis · Muscle & Nerve · 2017
A muscle-building drug for Duchenne muscular dystrophy showed promising trends but caused nosebleeds and spider veins, forcing the trial to shut down.
A small trial of a drug that blocks a muscle-limiting protein in boys with Duchenne muscular dystrophy found hints of benefit but also side effects that stopped the study early.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was like a small test to see if a new medicine is safe for boys with a muscle disease. The medicine showed some hints that it might help, but the results weren't strong enough to be sure. So we can't say the medicine works – we need a bigger test to know for sure.
What’s the bottom line?
Scientists tested a drug called ACE-031 in a small group of boys with Duchenne muscular dystrophy. The drug was meant to help muscles grow. The study was stopped early because some boys developed nosebleeds and spider veins.
How strong is this study?
The study was designed well: it was like a fair race where half the boys got the real medicine and half got a fake one (placebo), and nobody knew who got which. But the test was stopped early because of some side effects, so we didn't get to see the full results. That makes the findings less reliable than if the test had finished completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
63 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although the study is an RCT, it was stopped early due to safety concerns, and the primary outcome was safety. The efficacy outcomes showed only trends without statistical significance. Therefore, causation for efficacy cannot be established. For safety, the study can establish that ACE-031 was not associated with serious or severe adverse events, but the early termination limits causal inference for rare or long-term effects.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors are employees of Acceleron Pharma, the company that manufactures the investigational drug ACE-031 and likely funded the study. This employment creates a major conflict of interest.
Funders
Conflict Details
Acceleron Pharma: Employee (PhD) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (BS) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (MD) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (MD) at Acceleron Pharma during the study.
The study was terminated early due to safety concerns (epistaxis and telangiectasias). No explicit conflict of interest or funding statement was provided in the available text.
Key takeaways
- 01
Boys who got the drug did not have serious side effects, but they did not get significantly stronger or walk better than those who got placebo.
- 02
There were small hints of improvement in muscle mass and bone density, but the study was too small to be sure.
- 03
The results were not strong enough to say the drug works.
- 04
The side effects were a concern.
Surprising findings
- ACE-031 caused nosebleeds and spider veins, side effects not related to muscle.Myostatin is mainly known for regulating muscle mass. These vascular effects suggest the drug also hits receptors in blood vessels, which was not widely anticipated.
- Despite promising trends, none of the muscle or functional outcomes reached statistical significance.Given strong preclinical data, many expected a clearer signal. The small sample and early termination likely masked any real effect.
Practical takeaways
For families affected by DMD, stay informed about ongoing myostatin inhibitor trials but temper expectations.
This study was very small and terminated early. Results are preliminary, and other myostatin inhibitors may have different side effect profiles.
low confidenceFor content creators, use this study to discuss the gap between hype and reality in muscle drug development.
Be clear that the study's limitations (small sample, early termination, non-significant results) mean we can't draw firm conclusions.
medium confidenceWhy this study matters
The Promise and Peril of Myostatin Inhibition
ACE-031 blocks myostatin, a protein that limits muscle growth. In this small trial, boys on the drug maintained their 6-minute walk distance while placebo declined, and they gained lean mass and bone density while losing fat. But the study was terminated early because many boys developed nosebleeds (epistaxis) and spider veins (telangiectasias).
Myostatin inhibitors are often hyped as a 'muscle pill' for everyone from bodybuilders to the elderly. This study shows they might work for muscle wasting diseases, but also carry unexpected vascular side effects.
Trends That Didn't Reach Significance
The ACE-031 group showed a trend for maintaining 6-minute walk distance (mean change not reported exactly) compared to a decline in placebo, but this was not statistically significant. Similarly, lean body mass increased by about 1 kg more than placebo, and fat mass decreased, all non-significant.
In a rare disease like DMD, even non-significant trends can be encouraging. But with only about 10 boys per group, the study was underpowered to detect real differences.
Why the Study Was Stopped: Nosebleeds and Spider Veins
The trial enrolled 48 boys, but after the second dosing regimen, 2 of 16 boys in the ACE-031 group developed epistaxis and telangiectasias. No serious adverse events occurred, but the sponsor decided to stop the study due to these safety concerns.
It's rare for a study to be halted over what seem like minor side effects. This highlights how cautious researchers are with children, and how myostatin inhibition might affect blood vessels (via activin receptors).
The Hope and Hype of Myostatin Inhibitors
Myostatin inhibitors have been pursued for decades to treat muscle wasting conditions. This study is one of the first in DMD, and though it failed to show statistically significant benefits, the trends align with animal studies.
Many people think myostatin inhibitors are a sure thing for muscle growth. This study shows the reality: modest effects and unexpected side effects, reminding us that biology is complex.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a drug called ACE-031 in a small group of boys with Duchenne muscular dystrophy. The drug was meant to help muscles grow. The study was stopped early because some boys developed nosebleeds and spider veins.
Research results
Boys who got the drug did not have serious side effects, but they did not get significantly stronger or walk better than those who got placebo. There were small hints of improvement in muscle mass and bone density, but the study was too small to be sure.
What this means - more context
The results were not strong enough to say the drug works. The side effects were a concern.
To evaluate the safety, pharmacokinetics, and pharmacodynamics of the myostatin inhibitor ACE-031 in ambulatory boys with Duchenne muscular dystrophy (DMD).
In a small, early-terminated randomized controlled trial, ACE-031 was not associated with serious or severe adverse events, but did cause epistaxis and telangiectasias leading to study discontinuation. Non-significant trends for maintenance of 6-minute walk distance, increased lean body mass and bone mineral density, and reduced fat mass were observed.
Methods Used
Randomized, double-blind, placebo-controlled, ascending-dose trial; subcutaneous ACE-031 administered every 2–4 weeks to ambulatory DMD boys; primary outcome: safety; secondary: pharmacokinetics and pharmacodynamics.
Main Finding
No serious or severe adverse events, but dose-limiting epistaxis and telangiectasias led to early termination. Trends for pharmacodynamic effects (6MWT maintenance, lean mass increase, fat mass decrease) were not statistically significant.
Confidence Level
Low (small sample, early termination, non-significant results)
Study Flags
Red Flags
- •Early termination due to adverse events (epistaxis/telangiectasias)
- •Small sample size
- •Non-significant statistical results
Surprising Findings
ACE-031 caused nosebleeds and spider veins, side effects not related to muscle.
Myostatin is mainly known for regulating muscle mass. These vascular effects suggest the drug also hits receptors in blood vessels, which was not widely anticipated.
Practical Takeaways
For families affected by DMD, stay informed about ongoing myostatin inhibitor trials but temper expectations.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study was like a small test to see if a new medicine is safe for boys with a muscle disease. The medicine showed some hints that it might help, but the results weren't strong enough to be sure. So we can't say the medicine works – we need a bigger test to know for sure.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design reduces bias
- Clear primary objective: safety evaluation
- Use of validated outcome measures (6MWT, DEXA for body composition)
Weaknesses
- Early termination due to safety concerns reduces statistical power and may introduce bias
- Small sample size (number of participants not specified but likely small given early termination)
- Efficacy endpoints were secondary and not powered for statistical significance
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a drug called ACE-031 in a small group of boys with Duchenne muscular dystrophy. The drug was meant to help muscles grow. The study was stopped early because some boys developed nosebleeds and spider veins.
Research results
Boys who got the drug did not have serious side effects, but they did not get significantly stronger or walk better than those who got placebo. There were small hints of improvement in muscle mass and bone density, but the study was too small to be sure.
What this means - more context
The results were not strong enough to say the drug works. The side effects were a concern.
To evaluate the safety, pharmacokinetics, and pharmacodynamics of the myostatin inhibitor ACE-031 in ambulatory boys with Duchenne muscular dystrophy (DMD).
In a small, early-terminated randomized controlled trial, ACE-031 was not associated with serious or severe adverse events, but did cause epistaxis and telangiectasias leading to study discontinuation. Non-significant trends for maintenance of 6-minute walk distance, increased lean body mass and bone mineral density, and reduced fat mass were observed.
Methods Used
Randomized, double-blind, placebo-controlled, ascending-dose trial; subcutaneous ACE-031 administered every 2–4 weeks to ambulatory DMD boys; primary outcome: safety; secondary: pharmacokinetics and pharmacodynamics.
Main Finding
No serious or severe adverse events, but dose-limiting epistaxis and telangiectasias led to early termination. Trends for pharmacodynamic effects (6MWT maintenance, lean mass increase, fat mass decrease) were not statistically significant.
Confidence Level
Low (small sample, early termination, non-significant results)
Study Flags
Red Flags
- •Early termination due to adverse events (epistaxis/telangiectasias)
- •Small sample size
- •Non-significant statistical results
Surprising Findings
ACE-031 caused nosebleeds and spider veins, side effects not related to muscle.
Myostatin is mainly known for regulating muscle mass. These vascular effects suggest the drug also hits receptors in blood vessels, which was not widely anticipated.
Practical Takeaways
For families affected by DMD, stay informed about ongoing myostatin inhibitor trials but temper expectations.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study was like a small test to see if a new medicine is safe for boys with a muscle disease. The medicine showed some hints that it might help, but the results weren't strong enough to be sure. So we can't say the medicine works – we need a bigger test to know for sure.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design reduces bias
- Clear primary objective: safety evaluation
- Use of validated outcome measures (6MWT, DEXA for body composition)
Weaknesses
- Early termination due to safety concerns reduces statistical power and may introduce bias
- Small sample size (number of participants not specified but likely small given early termination)
- Efficacy endpoints were secondary and not powered for statistical significance
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was designed well: it was like a fair race where half the boys got the real medicine and half got a fake one (placebo), and nobody knew who got which. But the test was stopped early because of some side effects, so we didn't get to see the full results. That makes the findings less reliable than if the test had finished completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
63 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although the study is an RCT, it was stopped early due to safety concerns, and the primary outcome was safety. The efficacy outcomes showed only trends without statistical significance. Therefore, causation for efficacy cannot be established. For safety, the study can establish that ACE-031 was not associated with serious or severe adverse events, but the early termination limits causal inference for rare or long-term effects.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors are employees of Acceleron Pharma, the company that manufactures the investigational drug ACE-031 and likely funded the study. This employment creates a major conflict of interest.
Funders
Conflict Details
Acceleron Pharma: Employee (PhD) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (BS) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (MD) at Acceleron Pharma during the study.
Acceleron Pharma: Employee (MD) at Acceleron Pharma during the study.
The study was terminated early due to safety concerns (epistaxis and telangiectasias). No explicit conflict of interest or funding statement was provided in the available text.